{"product_id":"convatecgroup-five-forces-analysis","title":"Convatec Group Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eConvatec Group faces moderate supplier power, steady buyer negotiation, and intense rivalry from global medtech peers, while regulatory barriers temper new entrants and substitutes pose niche threats in wound care and ostomy products.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Convatec Group’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConvatec depends on certified medical-grade polymers, adhesives and precision electronics for infusion and wound-care devices; in 2024 about 62% of raw-material spend tied to polymers and adhesives, per company filings. \u003c\/p\u003e\n\u003cp\u003eBecause only a few suppliers meet ISO 13485 and USP \u0026lt;661\u0026gt; standards, supplier count is limited, giving them moderate pricing leverage—Convatec reported raw-material cost inflation of ~7% in 2023 that pressured margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Switching Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers in medical devices are embedded in Convatec Group’s regulatory filings, so switching needs fresh FDA\/EMA submissions, clinical re-validation and up to 12–24 months of testing, raising change costs by an estimated $5–15m per component in 2024 industry averages; this technical lock-in increases suppliers’ bargaining power versus Convatec.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Global Supply Chain Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy late 2025, improved global logistics cut transit delays by ~30% year-over-year, easing some supplier risk, but specialty chemical prices remain ~12% above 2022 levels, keeping input cost pressure on Convatec Group; the company uses multi-year supply contracts covering ~60% of key inputs and has expanded sourcing to four regions (Europe, US, India, China) to hedge disruptions. Still, loss of a single patented material supplier could halt lines and hit gross margins by an estimated 3–5% in a quarter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Integration and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupplier forward integration in electronic components—notably sensor and microcontroller suppliers investing in assembly—pushes Convatec (FTSE: CTEC) to co-develop products; Convatec reported 2024 R\u0026amp;D spend of £67m, so reliance on supplier R\u0026amp;D raises supplier leverage over pricing and roadmaps.\u003c\/p\u003e\n\u003cp\u003eThis dependence boosts bargaining power for tech-heavy suppliers, as ~30–40% of automated infusion set value comes from proprietary electronics, forcing longer contracts and joint IP terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 R\u0026amp;D: £67m\u003c\/li\u003e\n\u003cli\u003eElectronics value share: 30–40%\u003c\/li\u003e\n\u003cli\u003eForward integration increases supplier leverage\u003c\/li\u003e\n\u003cli\u003eRequires co-development and longer contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBulk Purchasing Power and Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvatec Group leverages its 2024 revenue scale—about $1.7bn in wound care and ostomy segments—to secure favorable terms with commodity suppliers, lowering input costs by competitive bidding for packaging and general plastics.\u003c\/p\u003e\n\u003cp\u003eThis bulk purchasing offsets supplier power from specialized material vendors for high-performance dressings, keeping gross margin pressure limited; procurement savings estimated at 1–2% of COGS in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue scale ~$1.7bn aids negotiation\u003c\/li\u003e\n\u003cli\u003eCompetitive bidding used for generic inputs\u003c\/li\u003e\n\u003cli\u003eProcurement savings ~1–2% of COGS (2024)\u003c\/li\u003e\n\u003cli\u003eScale mitigates specialist supplier leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration fuels cost inflation; Convatec hedges scale to protect margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is moderate-high: certified polymer\/adhesive and electronics suppliers are few, causing ~7% raw-material inflation in 2023 and 12% higher specialty chemical costs vs 2022; switching triggers 12–24 months of revalidation and ~$5–15m per component. Convatec hedges with ~60% multi-year contracts, four sourcing regions and scale (~$1.7bn wound\/ostomy 2024) trimming COGS 1–2%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue (wound\/ostomy)\u003c\/td\u003e\n\u003ctd\u003e$1.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e£67m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw-material inflation 2023\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty chemical cost vs 2022\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMulti-year coverage of key inputs\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching revalidation time\u003c\/td\u003e\n\u003ctd\u003e12–24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated revalidation cost per component\u003c\/td\u003e\n\u003ctd\u003e$5–15m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectronics value share\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated gross margin hit if single supplier lost\u003c\/td\u003e\n\u003ctd\u003e3–5% (quarter)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Convatec Group, this Porter's Five Forces overview uncovers key competitive drivers, supplier and buyer influence on pricing, threats from substitutes and new entrants, and disruptive forces that could impact its market share and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces snapshot for Convatec—ideal for quick strategic decisions and slide-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge hospital networks and group purchasing organizations account for an estimated of convatec revenue in wound ostomy care letting them demand double-digit volume discounts standardized regional pricing.\u003e\n\u003cptheir aggregated purchasing enabled a handful of gpos to steer contracts worth over annually in comparable peers so they can shift large tenders rivals and compress convatec margins.\u003e\n\u003c\/ptheir\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic health systems like the NHS (UK) and Medicare (US) set reimbursement caps that shape Convatec Group’s pricing for ostomy and wound care; NHS procurement saved ~£300m in 2023 via tariff changes, forcing suppliers to cut prices.\u003c\/p\u003e\n\u003cp\u003eWhen governments cut reimbursements—UK cuts in 2024 and proposed US Medicare fee adjustments for 2025—Convatec often must lower list prices or accept tender losses, compressing gross margins (Convatec reported 2024 gross margin ~61%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Brand Loyalty in Chronic Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpin convatec ostomy and continence care patients form strong product loyalty show retention after first year individual bargaining power is low once a fit found. this stickiness reduces price sensitivity in retail home-care channels supporting stable asps selling prices predictable revenue reported recurring growth of advanced wound ostomy. lower churn means payers distributors face less pressure to push discounts keeping margins steadier.\u003e\n\u003c\/pin\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs for Clinicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinicians trained on Convatec infusion sets and negative pressure wound therapy (NPWT) face measurable switching costs: retraining a nursing team can take 8–16 hours per clinician and reload protocols across wards, raising operational disruption and labor costs by an estimated $1,200–$3,500 per clinician transition (2024 hospital staffing data).\u003c\/p\u003e\n\u003cp\u003eThese time and training burdens reduce customer churn; industry surveys show device-brand loyalty rises by ~22% when vendors offer structured training.\u003c\/p\u003e\n\u003cp\u003eConvatec invests in clinical education and on-site support—its 2024 annual report cites sustained retention in core wound-care accounts and growing NPWT consumable spend per account, helping lock in recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetraining 8–16 hours per clinician\u003c\/li\u003e\n\u003cli\u003eTransition cost ~$1,200–$3,500 per clinician\u003c\/li\u003e\n\u003cli\u003eBrand loyalty +22% with vendor training\u003c\/li\u003e\n\u003cli\u003eConvatec 2024: rising NPWT consumable spend per account\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Transparency and Digital Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy 2025 digital procurement platforms raised price transparency in medtech; hospitals can compare Convatec prices to Coloplast and Smith \u0026amp; Nephew in minutes, cutting sourcing time by ~30% and pushing list-price discounts toward double digits.\u003c\/p\u003e\n\u003cp\u003eProcurement officers now demand value-based pricing and documented outcomes; 62% of hospital buyers in 2024 said clinical evidence drives contract awards, increasing pressure on Convatec’s margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% faster sourcing\u003c\/li\u003e\n\u003cli\u003eDouble-digit discounting pressure\u003c\/li\u003e\n\u003cli\u003e62% of buyers cite clinical evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Buyer Leverage vs Clinician\/Patient Stickiness: 35–45% Hosp\/GPO, 61% Margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphospital concentration revenue large tenders\u003e$200m, public reimbursement caps (NHS £300m saving 2023), Convatec 2024 gross margin ~61%, patient retention 65–75%, retrain 8–16h ($1,200–$3,500), sourcing 30% faster, 62% buyers cite evidence—net: high buyer leverage but clinician\/patient stickiness limits full price erosion.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHosp\/GPO rev%\u003c\/td\u003e\n\u003ctd\u003e35–45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge tenders\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin 2024\u003c\/td\u003e\n\u003ctd\u003e~61%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient retention\u003c\/td\u003e\n\u003ctd\u003e65–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/phospital\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eConvatec Group Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Convatec Group Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders, no mockups.\u003c\/p\u003e\n\u003cp\u003eThe document displayed is the same professionally written, fully formatted file you can download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final deliverable: ready for immediate use and identical to the document provided after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747267588473,"sku":"convatecgroup-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/convatecgroup-five-forces-analysis.png?v=1772196892","url":"https:\/\/growthsharematrix.com\/products\/convatecgroup-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}